NCT02969525 - A Study to Evaluate the Dose Response Based on the Efficacy, Safety and Tolerability of Bimekizumab in Subjects With Active Psoriatic Arthritis Which is a Type of Inflammatory Arthritis | Biotech Hunter

Enrollment

206

Participants

Timeline

Start Date

October 31, 2016

Primary Completion Date

November 30, 2017

Study Completion Date

July 31, 2018

Conditions

Psoriatic Arthritis

Interventions

OTHER

Placebo

DRUG

Bimekizumab

Bimekizumab in different dosage regimens.

Trial Locations (40)

16635

Pa0008 001, Duncansville

21740

Pa0008 003, Hagerstown

33180

Pa0008 005, Aventura

38305

Pa0008 010, Jackson

40504

Pa0008 025, Lexington

48910

Pa0008 011, Lansing

75150

Pa0008 013, Mesquite

75231

Pa0008 006, Dallas

92037

Pa0008 007, San Diego

97239

Pa0008 014, Portland

98122

Pa0008 002, Seattle

02919

Pa0008 012, Johnston

29406-93

Pa0008 004, Charleston

Unknown

Pa0008 205, Brno

Pa0008 207, Olomouc

Pa0008 201, Prague

Pa0008 202, Prague

Pa0008 209, Prague

Pa0008 210, Prague

Pa0008 203, Zlín

Pa0008 302, Cologne

Pa0008 309, Erlangen

Pa0008 304, Hamburg

Pa0008 301, Ratingen

Pa0008 403, Budakeszierdő

Pa0008 401, Veszprém

Pa0008 452, Bialystok

Pa0008 453, Elblag

Pa0008 456, Elblag

Pa0008 455, Krakow

Pa0008 451, Poznan

Pa0008 450, Torun

Pa0008 454, Warsaw

Pa0008 459, Warsaw

Pa0008 465, Wroclaw

Pa0008 604, Moscow

Pa0008 605, Moscow

Pa0008 607, Moscow

Pa0008 606, Saint Petersburg

Pa0008 608, Saint Petersburg

All Listed Sponsors

lead

UCB Biopharma S.P.R.L.

INDUSTRY